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SUMMARY 
In September 2003 a report was published on the impact of the REACH system on the need for 
further testing taking into account already existing obligations and voluntary initiatives and 
applying certain assumptions regarding the use of estimation techniques such as grouping of 
chemicals, read-across, (Quantitative) Structure-Activity Relationships ((Q)SAR) and the 
outcome of screening tests and risk assessments (Pedersen et al. 2003). The report was based on 
the interim version of the REACH Consultation Document of May 2003 and did not address the 
number of test animals needed for the testing. The present document is an addendum to the 
previous report and specifically aims at identifying the potential savings of vertebrate test 
animals that can be obtained through application of these alternative approaches. It is based on 
the revised Commission proposal of 29 October 2003. Moreover an update of the cost estimates 
presented in Pedersen et al. (2003) is included. 
The calculation of the test animals needed as a consequence of REACH has been carried out by 
using the same approach as employed by Pedersen et al. (2003). In this approach, the total 
amount of data required under REACH was established based on the information requirements 
as included in Annexes V – VIII of the legislative proposal. Then the amount of currently 
available data, as well as the data already promised under various programmes, was determined. 
The impact on the testing needs of so-called intelligent testing strategies applying methodologies 
such as (Q)SAR, grouping, read-across and possibilities for waiving according to Annex IX of 
REACH was assessed assuming three scenarios: 1) a standard scenario representing an average 
situation regarding acceptance of these methods, 2) a scenario based on minimum acceptance, 
and 3) a scenario with maximum acceptance. The currently available and expected data as well 
as the effect of the use of these methodologies were then ‘subtracted’ from the total quantity of 
data required under REACH, resulting in the estimated test requirements.  
The number of vertebrate test animals needed for the individual endpoints was established by 
consulting test laboratories and this was multiplied by the estimated number of studies required 
under REACH, resulting in estimates of the total amount of test animals which will potentially 
be needed for the implementation of the REACH legislation.  
The results of these calculations show that approximately 3.9 million additional test animals 
could potentially be used as a consequence of the introduction of REACH if the use of 
alternative methods is not accepted by regulatory authorities. However, a considerable reduction 
in animal use can be obtained if these techniques would be applied more intensively. The 
standard scenario based on average acceptance of these methods indicates potential savings of 
1.3 million test animals. Maximum acceptance of these techniques would even enhance this 
saving potential to 1.9 million test animals. These savings can be obtained by introducing and 
accepting methods that are to a large extent available today.  
Based on the average acceptance scenario, the estimated number of vertebrate test animals is 2.6 
million animals (mammals, birds and fish) over a time period of 11 years (i.e. the time period for 
the full implementation of REACH), or 240,000 animals per year. This equates to 2-3% of the 
total number of vertebrate test animal used per year for experimental and other scientific 
purposes, including pharmaceutical testing, based on the 1999 figure of 9.8 million animals (EC, 
2003b). After the implementation period of REACH, the number of test animals will most likely 
return to a base-line level corresponding to the notifications of new substances put on the market. 
By then, however, the huge knowledge gap we currently face for widely used existing chemicals 
will have been closed, enabling safer use of chemicals for the generations to come. 
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The overall direct testing costs based on the most likely scenario have been estimated at 1.5 
billion EURO. This differs only slightly from the 1.6 billion EURO estimated in the 2003 
Pedersen report. The average test costs per substance in the tonnage band from 1 – 10 tonnes per 
year is, however, reduced significantly compared to earlier estimates as a result of the reduced 
data requirements in Annex V (7,700 versus 12,100 Euro), whereas the costs per substance in the 
higher tonnage bands are only changed slightly. About 90% of the costs are attributed to human 
health related endpoints.  
Applying intelligent testing strategies could reduce the need for tests by up to 70% for individual 
endpoints resulting in significant savings in testing costs and use of animals. Estimates 
considering the minimum and maximum use of (Q)SAR, grouping, read-across and possibilities 
for waiving show that the number of test animals required depends strongly (up to a factor of 
nearly 4 for various endpoints) on the success and acceptance of these methodologies. For some 
of the test animal intensive endpoints, no alternative testing is currently available, which 
effectively reduces the impact that these methods might have on animal testing. Therefore it is 
recommended that the current activities in the EU and the OECD as well as in industry and 
academia on the development, validation and adoption of both (Q)SAR methods, in vitro testing 
and read-across techniques (i.e. intelligent testing strategies) are intensified and focused on those 
endpoints that incur the highest benefits regarding reduction of test animal use and costs.  
Increasing the efficiency, cost-effectiveness and focus of the risk assessment process, using new 
scientifically-sound techniques for creating and interpreting relevant data is essential. Such an 
approach can lead to a significant reduction in direct testing costs, the use of animals and speed-
up the risk assessment process (Bradbury et al., 2004). 
The Joint Research Centre (JRC) Activity on (Q)SARs, established under the JRC Work 
Programme for 2003-2006 and coordinated by the European Chemicals Bureau (ECB), is one of 
the actions by the Commission that is aimed at promoting the implementation of (Q)SARs and 
other estimation approaches. In addition, during the implementation of the Commission’s interim 
strategy for REACH one of the REACH Implementation Projects (RIP 3.3) will focus on 
developing guidance on information requirements on intrinsic properties of substances, aiming in 
particular at developing intelligent testing strategies which should allow minimal use of test 
animals. 
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1 INTRODUCTION 
On October 29
th
, 2003 the European Commission published its proposal for a regulation 
concerning Registration, Evaluation and Authorisation of Chemicals (REACH) (EC 2003a). This 
proposal was preceded by an internet Consultation Document concerning REACH which was 
published by DG ENTR and DG ENV in May 2003. The draft REACH legislation addresses one 
of the key issues for chemicals - the lack of publicly available data on chemicals, a gap identified 
over 20 years ago. 
Based on the text of the REACH consultation document the Joint Research Centre published in 
September 2003 a report entitled ‘Assessment of additional testing needs under REACH’ 
(Pedersen et al., 2003). This report evaluated the need for further testing under REACH taking 
into account already existing obligations and voluntary industry initiatives, and based on a 
number of assumptions regarding the use of estimation techniques such as (Q)SARs and the 
outcome of screening tests and risks assessments. The report by Pedersen et al. focussed on the 
testing costs for REACH but did not address the number of vertebrate test animals that could 
potentially be used as a consequence of implementing the new legislation. The present document 
is an addendum to the previous report and specifically aims at identifying the potential savings of 
vertebrate test animals that can be obtained through application of these alternative approaches. 
The method applied and the assumptions made are largely similar to the analysis carried out in 
the original report. 
The assessment presented in this report is based on the final REACH proposal as published in 
October 2003 (EC 2003a). This means that the reduced Annex V- requirements, i.e. the 
exclusion of tests for cytogenicity for mammalian cells, growth inhibition in algae and the ready 
biodegradability from Annex V, are considered in this paper. These changes however, do not 
impact the number of vertebrate test animals, but do have an impact on the cost estimates (see 
section 4.2). Finally, it should be noted that Pedersen et al. did not consider the impact of 
increased use of in vitro methods as an alternative to whole animal testing, which is also the case 
with the present document
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2 PROCEDURE 
A stepwise procedure was used for estimating the total testing needs as a consequence of 
REACH (EC, 2003a). Only testing needs directly incurred by REACH in addition to testing 
already required under current legislation and testing already conducted or promised to be 
conducted by industry as a result of voluntary initiatives have been taken into account. The 
following stepwise approach has been followed: 
1. Identification/estimation of number of substances within the volume bands for testing 
requirements 
2. Identification of existing data coverage for High Production Volume Chemicals (HPVCs) 
3. Estimation of likely data coverage for non-HPVCs 
4. Identification of data to be provided by voluntary initiatives 
5. Identification of possibilities for use of intelligent testing strategies, e.g. (Quantitative) 
Structure-Activity Relationships ((Q)SAR), grouping, read-across and possibilities for 
waiving. 
6. Assessment of likely acceptance of waiving and requests for further testing 
7. Estimation of number of tests needed for each endpoint for each tonnage band 
8. Estimation of the number of test animals required for the different endpoints 
For each of the endpoints for which data are required according to Annexes V to VIII of the 
REACH Document and for each of the four tonnage bands, the data coverage resulting from the 
following four elements was established: 
x Amount of available data 
x Data promised under various programmes 
x Impact of (Q)SAR, grouping and read-across methods 
x Waiving (for other reasons as, e.g., unlikely exposure) 
The resulting test needs for each endpoint and tonnage band were then estimated as total testing 
requirements minus the estimated data already covered by the four elements mentioned above. 
The REACH legislation strongly promotes and in the case of vertebrate animal testing actually 
requires sharing of test data between companies, and it will provide the tools needed. For this 
reason duplicate testing is assumed not to take place and if it were to take place, it is considered 
to be the result of a voluntary initiative from industry, and not as a direct consequence of the 
REACH legislation. Therefore, data sharing was assumed for each substance resulting in one test 
package per substance. 
For a discussion of the various considerations regarding data coverage for each endpoint, the 
reader is referred to the paragraphs 2.1 to 2.7 in Pedersen et al. (2003). It is noteworthy, 
however, that for the developmental toxicity study (endpoint 6.7.2 in REACH) it is assumed that 
the test is carried out in two species. This has been taken into account in both the estimates of 
test animals needed as well as the cost estimates. However, it is likely to be an overestimation as 
a second study in a different species will often be waived and only required in case of a negative 
result in the first test. 
The information on testing needs for the individual endpoints, combined with an estimate of the 
numbers of substances provided the matrix on the basis of which the need for vertebrate test 
animals was calculated. For the test animal estimate the following studies were considered 
(numbers indicate the REACH reference number): 
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6.2.1 In vivo eye irritation  
6.3 Skin sensitisation  
6.4.4 Further mutagenicity studies  
6.5.1 Acute oral toxicity  
6.5.2 Acute inhalation toxicity 
6.5.3 Acute dermal toxicity  
6.6.1 Short-term repeated dose toxicity  
6.6.2 Sub-chronic toxicity  
6.6.3 Long-term repeated dose toxicity 
6.7.1 Developmental toxicity screening study  
6.7.2 Developmental toxicity study  
6.7.3 Two-generation reproductive toxicity study 
6.9 Carcinogenicity 
7.1.3 Short-term fish toxicity 
7.1.6 Long-term fish toxicity  
7.3.2 Accumulation in aquatic species  
7.6 Long-term bird toxicity 
NB: for Toxicokinetics (endpoint 6.8.1) the legislative text assumes ‘assessment of the 
toxicokinetic behaviour of the substance to the extent that can be derived from the relevant 
available information’. 
To estimate the total amount of test animals anticipated as a consequence of REACH, the 
number of test animals needed for each endpoint study had to be established. For the 
environmental studies, information was provided by a Danish consultancy firm (DHI). For all 
other studies, a Dutch institute (TNO) has been consulted on how many animals are normally 
(average) used for the different toxicity tests, including the minimum and maximum range. Both 
firms are considered to have extensive experience with carrying out (eco) toxicology studies 
and/or experience in preparing dossiers for submission to regulatory authorities. The estimates 
on the mammalian and non-mammalian test animals (birds, fish and fish eggs) required per study 
type/endpoint are provided in Appendix I. 
To clarify how the average number and the range (min – max) of test animals anticipated to be 
used has been calculated the following should be noted. As the testing guidelines are not always 
explicit on how a toxicity study should be conducted, the numbers of test animals required for a 
certain endpoint study might vary. Most figures in Appendix I are based on the content of the 
test guidelines. Where an expert judgement was employed for interpretation or providing a 
typical animal use estimate, this is indicated. In addition, where more than one test was available 
for the same endpoint, the figure representing the most commonly used endpoint study was 
applied in the calculation (light blue background). Finally, in some cases the ‘average’ number 
of test animals used equals the ‘maximum’ number of test animals used. This is where a limit or 
minimal test (with fewer animals) cannot provide the requested / intended information and a full 
test would be used. More details are available in the footnotes of the Table in Appendix I.  
Regarding the calculated numbers of test animals per endpoint the following should be noted. In 
the case of in vivo skin and eye irritation it has not been taken into account that the test animals 
can be re-used for new studies. Also, the amount of animals anticipated for range finding has not 
been taken into account, as it is assumed that for filling in the currently existing data gaps, the 
studies have to be carried out for substances for which some information on the toxicity of the 
substance is already available. Therefore, range finding studies would be needed in only a 
limited number of cases. It should also be noted that for endpoint 6.7.2, the developmental 
toxicity study, it has been assumed that this study will be carried out in two species. This we 
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consider a conservative approach, especially taking into account the large contribution of this 
endpoint to the total amount of test animals required, as the second study is required only when 
the outcome of the first test is negative. It should be noted that for the two-generation 
reproductive toxicity study and the developmental toxicity study, offspring have not been taken 
into account. 
The extent to which (Q)SAR and read-across can be used as an alternative to animals test has 
been demonstrated in the US Challenge Program for HPV substances (Bradbury et al. 2004) 
(Table 2.1). Of the data needed on human health endpoints, 50% was covered by previously 
unpublished studies submitted by the industry whereas 44% of the data was estimated by use 
(Q)SARs and read-across methods (in fact 88% of the remaining data gap). Only 6% therefore 
needed to be obtained by testing. For environmental data, 58% of the missing data was available 
as unpublished studies, 35% were estimated by use of (Q)SARs and read across methods (in fact 
83% of the remaining data gaps) and 7% were obtained from tests. 
Table 2.1    Experience from the US HPV Challenge Program (Auer, 2004) 
 Human health Environmental effects 
Adequate studies 50 % 58 % 
Estimation 44 % 35 % 
Testing 6 % 7 % 
Three different scenarios were applied for estimating the impact of alternatives to animals 
testing: 1) a standard scenario reflecting the current practices on acceptance of (Q)SAR, 
grouping, read-across and possibilities for waiving, but not taking into account possible new 
techniques, 2) a scenario assuming minimal acceptance, and 3) a scenario assuming maximum 
acceptance of these methods (including techniques to be developed in coming years). The 
scenarios are described in detail in Pedersen et al. (2003) and the main assumptions regarding 
use of these alternatives methods are summarised below. 
In estimating the number of test animals assuming the ‘standard’ scenario of (Q)SAR, grouping, 
read-across and possibilities for waiving, it was assumed that for 70% of the substances 
produced in < 1,000 tonnes/year (non-HPVCs), (Q)SARs and read-across will be accepted where 
no data are available. This is about 10 – 20% lower than the actual use of these techniques in the 
U.S. HPV Challenge Program (Bradbury et al., 2004).  Furthermore for the endpoints not 
covered by the U.S. HPV Challenge Program, but where estimation techniques have already 
been developed, an assessment was made by the Danish EPA on the quality of the (Q)SARs for 
the different endpoints. Depending on the scores granted by the EPA, ranging from good, fair to 
poor, it was assumed that respectively 60%, 30% and 0% of the test needs could be covered by 
(Q)SARs.  
In order to calculate the total number of test animals in the scenario assuming minimal use of 
(Q)SAR, grouping, read-across and possibilities for waiving, similar levels of acceptance of 
(Q)SARs were used as in the business impact study which was carried out by RPA (2003). 
Further details can be found in Pedersen et al. (2003). 
For calculating the scenario assuming maximum acceptance of (Q)SAR, grouping, read-across 
and possibilities for waiving it was assumed that the approach already used today under the U.S. 
HPV Challenge Program will also be accepted in the EU. Hence, the same acceptance 
probability for the endpoints1 covered was used for non-HPVCs as for the HPVCs (substances 
                                                 
1 The applied acceptance of (Q)SAR and read-across (70%) was lower than in the US-EPA HPV Challenge Program 
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produced in > 1,000 tonnes/year). For the endpoints not covered by the U.S. HPV Challenge 
program, but where estimation techniques have already been developed, scores were assigned 
based on the assessment by the Danish EPA. These ranged from good, fair to poor, leading to the 
assumption that 80%, 40% and 10%, respectively, of the test needs can be covered by (Q)SARs. 
The cost estimate is based on the approach used by Pedersen et al. (2003) and applies the 
estimated number of tests required under REACH under the assumptions regarding alternatives 
to animal tests discussed above. The costs of the individual tests are taken from the Business 
Impact Study carried out by RPA (2003) unless noted otherwise in the spreadsheets (available 
from the ECB website).  
                                                                                                                                                             
where (Q)SAR/read-across acceptance was about 80-90%. 
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3 RESULTS  
The estimated number of tests needed for the different data endpoints, expressed as the 
percentage of the total number of phase-in substances, is presented in Figure 1. The estimate 
takes into account the basic information requirements for each tonnage band, the already 
available tests, the tests industry has already committed to, the possible use of (Q)SARs, 
grouping and read-across and the possibilities for waiving. 
Based on these assumptions it is estimated that the skin sensitisation test is the test that needs to 
be conducted for most of the phase-in substances (35%) followed by further mutagenicity tests 
(22%) and the eye irritation test (18%). Other endpoints involving vertebrate test animals are 
required for 10% or less of the total number of phase-in substances.  
Table 3.1 provides an overview of the estimated test animal needs over an implementation 
period of 11 years for the three scenarios described in Section 2. The min-max range indicates 
the corresponding calculations using ‘minimum test animals’ per study and ‘maximum test 
animals’ respectively for the different end point studies (see Table in Appendix I). 
Table 3.1    Test animal needs under REACH (in millions) over an implementation period of 11 years. 
Scenario Average no. animals min-max3 
Mammalian   
Standard use of (Q)SAR etc.1 2.4 2.0 - 2.8 
Min. use of (Q)SAR etc.1 3.5 2.8 - 4.1 
Max. use of (Q)SAR etc.1 1.9 1.6 - 2.2 
Non-mammalian
2
   
Standard use of (Q)SAR etc.1 0.23 0.19 - 0.27 
Min. use of (Q)SAR etc.1 0.40 0.35 - 0.51 
Max. use of (Q)SAR etc.1 0.16 0.13 - 0.18 
Total test animals    
Standard use of (Q)SAR etc.1 2.6 2.2 - 3.1 
Min. use of (Q)SAR etc.1 3.9 3.2 - 4.6 
Max. use of (Q)SAR etc.1 2.1 1.7 - 2.4 
1. (Q)SAR, grouping, read-across and possibilities for waiving 
2. Birds, fish and fish eggs 
3. Based on estimated minimum and maximum animal use per study  
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Figure 1      Estimated percentage of the total number of phase-in substances that will need to be tested for the different 
endpoints. 
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The results in Table 3.1 show that when assuming the use of alternatives to animal testing 
corresponding to the ‘standard’ scenario described in the previous section, the total sum of 
mammalian and non-mammalian animals needed under REACH is estimated at 2.6 million (2.2-
3.1). Of this total, 2.4 million animals will be mammalian and 0.23 million non-mammalian. As 
mentioned earlier, this calculation uses the assumption that the developmental toxicity study is 
carried out in two species. If only one developmental toxicity study is carried out the number of 
mammalian test animals would amount to 2.1 million (1.7 – 2.4). 
Table 3.1 also indicates the effect of a best-case scenario (assuming maximum use of (Q)SAR, 
grouping, read-across and possibilities for waiving) versus a worst-case scenario (assuming 
minimum use of these methods). If the use of alternative methods is applied and accepted more 
extensively by regulatory authorities the number of mammalian test animals could be reduced 
from 4.1 to 1.6 million (a difference of about a factor 2.6) and the number of non-mammalian 
test animals from 0.51 to 0.13 million (a difference of a factor of almost 4). Hence the potential 
impact of using intelligent testing strategies on the total number of test animals required under 
REACH is significant. The impact, however, is reduced due the lack of alternative methods for 
certain endpoints for which existing in vivo studies require a high number of test animals (e.g. 
reproductive toxicity testing). 
Figure 2 provides an overview of the estimated test animal needs for the different endpoint 
studies in the implementation phase of REACH. This figure indicates a major reason for the 
limitation of alternative testing on the estimated use of test animals. Currently no alternatives to 
animal testing are available for the three main contributors to the overall test animal use (two-
generation reprotoxicity, further mutagenicity (in vivo) studies, and developmental toxicity 
studies), which contribute with 72% to the total test animal need. For the next three main 
contributors (skin sensitisation, long-term fish studies, and accumulation) the acceptance of the 
(Q)SAR is considered to vary from 10 – 37%. This suggests that further exploration of 
alternative testing and promotion of the acceptance of existing alternative testing methods is 
strongly needed. 
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Figure 2      Estimated test animal need for the different endpoints. 
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4 DISCUSSION  
4.1 TEST ANIMALS 
The results presented in this report show that approximately 3.9 million additional test animals 
could potentially be used as a consequence of the introduction of REACH if the use of 
alternative methods is not accepted by regulatory authorities. However, a considerable reduction 
in animal use could be obtained if these techniques are applied more intensively. The impact of 
(Q)SAR, grouping, read-across and possibilities for waiving in place of test animals, is notable 
but limited if compared to the total number of test animals required under REACH, due to the 
lack of suitable alternatives to animal testing for the highest contributors (which accounts for 
72% of the test animals used as a consequence of REACH). 
The estimated total amount of animals used for experimental and other scientific purposes in 
1999 was 9.8 million (COM(2003)). About 10% of these are used for toxicological and other 
safety evaluations. The remaining 90% are used in: 
x biological studies of a fundamental nature; 
x research and development of human medicine, dentistry and veterinary medicine 
x production and quality control of human medicine, dentistry and veterinary medicine 
x education and training 
x diagnosis of disease 
x and other purposes 
The 10% of animals used for toxicological and other safety evaluations include those for safety 
evaluation of products and devices for human medicine and dentistry and for veterinary 
medicine. This includes about 150,000 animals used for testing of ‘products/substances falling 
under the scrutiny of authorities concerned with safety of health and of the environment by 
chemical products’, such as industrial chemicals and pesticides corresponding to about 1.5% of 
the test animals used in 1999. 
Using the standard scenario, the estimated number of vertebrate test animals potentially needed 
for the implementation of REACH is 2.6 (2.2-3.1) million over a time period of 11 years, i.e. the 
time period for full implementation of REACH. This corresponds to about 240,000 animals per 
year, or 2 - 3 % of the test animals used in 1999.  
The anticipated increase of overall test animal use as a consequence of REACH will last for a 
time period of 11 years, while knowledge on currently widely used chemicals that has been 
lacking for years will be acquired, enabling a safer use of chemicals for generations to come. 
After the implementation period, the testing requirements will return to a base level 
corresponding to the number of new registrations. 
It should be noted that the use of test animals for new chemicals under REACH will actually be 
lower than under the existing legislation due to the reduced data requirements at the tonnage 
band under 10 tonnes per year. To illustrate this, the base set for new chemicals under the current 
legislation include in vivo acute toxicity, skin irritation, eye irritation, skin sensitisation, a 28-day 
repeated-dose toxicity study, and an acute toxicity test in fish. This amounts to about 109 test 
animals per chemical, according to Appendix I. The base set is required for all chemicals 
registered from 1 tonne and higher in the current New Chemicals legislation. In REACH the 
requirements are considerably reduced for the tonnage band 1– 10 tonne, where the only test 
requiring vertebrates is the skin sensitisation test (23 animals, according to Appendix I). 
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Currently, about 120 new chemicals are registered in this tonnage band each year. Under the new 
legislation, this would therefore reduce the animals required over an 11 year time period by 
about 144,000 animals, compared to the current chemical legislation. Moreover, at present most 
test animals are used for acute toxicity studies, while REACH focuses on long-term endpoints 
that are more relevant for the assessment of human health, i.e. reproductive toxicity and 
mutagenicity. 
It should be emphasised that the estimates could be further reduced by including the further 
development and acceptance of (Q)SAR, grouping, read-across and possibilities for waiving as 
well as other approaches like thresholds for toxicological concern (Kroes et al. 2004), provided 
that this development is focused on the endpoints where the benefit in terms of reduction of 
animal use and costs is highest. Increasing the efficiency, cost-effectiveness and focus of the risk 
assessment process, using new scientifically-sound techniques for creating and interpreting 
relevant data is essential. Such an approach can lead to a significant reduction in direct testing 
costs and the use of animals and could speed-up the risk assessment process considerably 
(Bradbury et al., 2004). 
4.2 TEST COSTS 
The cost for the testing requirements in the implementation period of the final REACH proposal 
from October 2003 is estimated at 1476 Million EURO (range: 1,143-2,274 Million EURO, 
representing the different scenarios). This is slightly lower that estimated earlier based on 
Consultation Document from May 2003: 1561 Million EURO (range: 1180-2423 Million 
EURO) (Pedersen et al. 2003). The difference is mainly due to the reduced test requirements at 
the tonnage band from 1-10 tonnes per year, where the estimated test cost per substance is 
reduced from 12,100 EURO to 7,700 EURO. In both cases the calculations are made under the 
assumptions described in Section 3. The cost per substance in the higher tonnage bands remains 
more or less the same. 
Of the estimated costs over 11 years at about 1.5 Billion EURO, 32% is attributed to the 
developmental toxicity studies, 25% to the two-generation reproductive toxicity studies, 9% to 
the in vivo mutagenicity studies (further mutagenicity), and 8% to the sub-chronic toxicity 
studies. Other endpoints account for less than 5% of the total costs each.    
The testing requirements and the costs depend on the produced quantity of a substance. In the 
standard scenario, the total testing costs are distributed over the different tonnage bands as 
follows: 10% (1-10 tonnes/year), 25% (10-100 tonnes/year), 27% (100-1,000 tonnes/year), and 
38 % (> 1,000 tonnes/year). Consequently the main financial burden will be on the substances 
with the highest tonnage levels. 
As already indicated in Pedersen et al. (2003), the testing cost per produced tonne is much higher 
in the lowest tonnage bands, if the test costs are considered for an average substance. The test 
cost is 255 EURO/tonne for a substance produced with a volume of 3 tonnes/year and 7 
EURO/tonne for a substance produced in 3,000 tonnes/year.
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5 CONCLUSION  
The current document describes the impact of implementing the REACH proposal of October 
2003 on animals used for testing purposes as well as on the direct testing costs. Only the effect of 
REACH in addition to existing obligations of the current legislation or voluntary initiatives 
regarding submission of data on substances has been considered.  
The estimates are based on the ECB’s current understanding of how the testing strategy and 
adaptation rules will be implemented. The background and method as well as the estimated 
number of phase-in substances are the same as used by Pedersen et al. (2003). The information 
on number of test animals used in different tests was not, however included in the Pederson 
report. This means the estimates are based on the information available to the ECB regarding 
number of substances, availability of data, ongoing initiatives on providing data by industry and 
other sources, possibilities for use of (Q)SAR, grouping, read-across and waiving, or requiring 
tests based on current risk assessment considerations.  
According to the estimates, the highest numbers of test are required for the endpoints skin 
sensitisation (35%), further (in vivo) mutagenicity studies (22%), and eye irritation (18%). Other 
endpoints involving vertebrate test animals are required for 10% or less of the phase-in 
substances.  
The results presented in this report show that approximately 3.9 million additional test animals 
could potentially be used as a consequence of the introduction of REACH if the use of 
alternative methods is not accepted by regulatory authorities. However, a considerable reduction 
in animal use could be obtained if these techniques are applied more extensively. The standard 
scenario based on average acceptance of these methodologies indicates potential savings of 
1.3 million test animals. Maximum acceptance of these techniques would even enhance this 
saving potential to 1.9 million test animals. 
Of the total amount of test animals that could potentially be used under REACH, about 72% will 
be required for carrying out two-generation reproductive toxicity studies, developmental toxicity 
studies and further mutagenicity (in vivo) studies. 
The estimated number of test animals required for the implementation of REACH is about 
240,000 animals per year, which equals to 2 - 3 % of the test animals used in 1999 for 
experimental and other scientific purposes. 
The anticipated increase of the overall test animal use will last for a limited time period of 11 
years (the implementation period for REACH), enabling knowledge about currently widely used 
chemicals that has been lacking for years to be acquired, and providing better basis for safe use 
of chemicals for generations to come. Moreover, compared to the existing legislation, the need 
for test animals per registered substance is much lower in the tonnage band from 1 – 10 tonne 
per year, as specified in Section 4.1. 
It is emphasised that the expected further development of (Q)SARs and improved acceptance of 
(Q)SAR, grouping, read-across and possibilities for waiving, will most likely reduce the 
presented estimates, e.g. by focusing the development of alternative methods on endpoints where 
the benefit will be highest in terms of reduced use of test animals as well as costs. 
The direct testing costs resulting from the REACH proposal of October 2003 have been 
estimated at about 1.5 Billion EURO assuming use of alternatives to animal testing 
corresponding to the described standard scenario. The main difference from the estimates 
published earlier (Pedersen et al. 2003) is the lower price for tests per substance in the 1-10 
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tonnage band, where the costs is reduced from 12,100 EURO to 7,700 EURO, due to the reduced 
test requirements in Annex V. Almost 90% of the total direct testing costs are attributed to the 
human health studies. Furthermore, it is estimated that of these costs, about 32% is attributed to 
the developmental toxicity studies, 25% to the two-generation reproductive toxicity studies, 9% 
to the in vivo mutagenicity studies and 8% to the sub-chronic toxicity studies.  
The testing requirements and the costs depend on the produced quantity of a substance: 10% 
(1-10 tonnes/year), 24% (10 -100 tonnes/year), 27% (100-1,000 tonnes/year), and 38 % 
(> 1,000 tonnes/year). 
It should be noted for some of the most test animal intensive endpoints, no alternative tests are 
currently available. Therefore it is recommended that the current activities in the EU and the 
OECD as well as in industry and academia on the development, validation and adoption of both 
(Q)SAR methods and in-vitro tests are intensified and focused on endpoints that incur the most 
benefits from both a test animal and cost perspective.  
The Joint Research Centre (JRC) Activity on (Q)SARs, established under the JRC Work 
Programme for 2003-2006 and coordinated by the European Chemicals Bureau (ECB) is one of 
the actions by the Commission that is aimed at promoting the implementation of (Q)SARs and 
other estimation approaches. In addition, during the implementation of the Commission’s interim 
strategy for REACH, one of the REACH Implementation Projects (RIP 3.3) will focus on 
developing guidance on information requirements on intrinsic properties of substances, aiming in 
particular at developing intelligent testing strategies which should allow minimal use of test 
animals.  
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Appendix 1    Estimation of the number of test animals (vertebrates) used per test 
1. Note to the table: The testing guidelines are not always explicit on how a toxicity study should be set up and therefore some of the 
numbers might vary depending on the study set up and/or study laboratory.  Most figures in the table are based on the content of 
the test guidelines. Where an expert/expert judgement is employed for interpretation or providing a typical animal use estimate, 
this is indicated. 
2. Note to the table: In case of the possibility of a selection of one test out of several tests for the same endpoint, the figures presented 
in the row with the light blue background were used in the calculations. 
3. Note to the table: In some cases the ’normal’ number of test animals used equals the ‘maximum’ number of test animals used. In 
cases where a limit test can not provide the requested/ intended information a full test will be used. 
 Method  
(Annex V and 
OECD) 
Title Min  (Limit2) 
Control/treated 
Max Full Test 
Control/treated 
Normally Comments 
 
6.1.1 In vivo skin irritation  B.4 Acute toxicity (skin 
irritation) 
1 3 1 - 3 23  
6.2.1 In vivo eye irritation  B.5 Acute toxicity (eye 
irritation) 
1 3 1 - 3 23  
 Skin sensitisation  
 
  16 25 25 233 LLNA is the 
preferred test for 
REACH4 
 Classical B.6 Skin sensitisation 5/10 30 10/20 153  
                                                 
2 limit test = usually this means one high ( 2000 mg/kg normally) dose group and one control group. Limit test  Min, but normally they imply the same number of test animals. When such a test is 
available this is indicated between brackets ‘(limit)’. 
3 estimate after consultation with a Dutch test laboratory, TNO. 
4 The ‘base set’ required for Annex V and Annex VI (1 – 10 tonnes and up) under REACH is equal to the skin sensitization test (23 animals). The base set for New Chemicals (NC)  required for all 
chemicals registered from 1 tonne and up consist of an in vivo acute toxicity test (two routes, oral 8 and dermal 10), skin irritation (2), eye irritation (2), skin sensitization (23), a 28-day repeated dose 
toxicity (50) and an acute toxicity test in fish (14), totaling 109 test animals.  
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 Method  
(Annex V and 
OECD) 
Title Min  (Limit2) 
Control/treated 
Max Full Test 
Control/treated 
Normally Comments 
 LLNA B.42 LLNA 4(+4)/12  25 5(+5)/15 233 Currently 
 carried out  
with controls (+ n),  
over  time omitted 
6.4 Mutagenicity 
6.4.4  In vivo mutagenicity studies (one 
of these tests is carried out) 
  25 50 50 503 Min based on  
waiver for one sex 
 B.11 Mutagenicity - In 
vivo mammalian 
bone-marrow 
chromosome 
aberration test 
10/(10+10) (limit) 50 10+10/30+interim5 50 In some cases 
there is a waiver 
for one sex (- 25) 
 B.12 Mutagenicity - In 
vivo mammalian 
erythrocyte 
micronucleus test 
10/(10+10) (limit) 50 10+10/30+interim 30 Often the limit test  
is carried out 
6.5 Acute toxicity 
6.5.1 By oral route 
 (one of these tests is carried out) 
  3 9 6 - 9 83 Usually B.1 tris is 
carried out 
 B.1 bis Acute toxicity 
(oral) fixed dose 
method 
3/3 9 6 - 9 83  
 B.1 tris Acute toxicity 
(oral) – Acute 
3 9 6 - 9 83  
                                                 
5 interim = the additional animals added to the test group in case of possible interim sacrifices 
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 Method  
(Annex V and 
OECD) 
Title Min  (Limit2) 
Control/treated 
Max Full Test 
Control/treated 
Normally Comments 
toxic class method 
6.5.2 By inhalation B.2 Acute toxicity 
(inhalation) 
10/10 (limit) 40 10/30 203 Usually limit test  
is 
 carried out 
6.5.3 By dermal route B.3 Acute toxicity 
(dermal) 
5/5 (limit) 20 5/15 103 Usually limit test is 
 carried out 
6.6 Repeated dose toxicity 
6.6.1  Short-term repeated dose toxicity 
study (28 days)  (the most relevant test 
(exposure route) is carried out) 
  20 60 40 - 60 503 Usually no limit 
test is used for 
sub acute 
 Oral B.7 Repeated dose 
(28 days) toxicity 
(oral) 
10/10 (limit) 
 
60 10/30 +  
interim (=20) 
503  
 Inhalation B.8 Repeated dose 
(28 days) toxicity 
(inhalation) 
NA 60 10/30 +  
interim (=20) 
503  
 Dermal B.9 Repeated dose 
(28 days) toxicity 
(dermal) 
10/10 (limit) 60 10/30 +  
interim (=20) 
503  
6.6.2  Sub-chronic toxicity study (90-
day) (only one of the following tests is 
carried out) 
  16 32 32 323 In general B.27 is 
carried out 
 B.26 Sub-chronic oral 
toxicity test. 
20/20 (limit) 120 20(+20)/60  
+ interim (=20) 
806  
                                                 
6 IEH (2001):   Assessment of the Feasibility of Replacing Current Regulatory In Vivo Toxicity Tests with In Vitro Tests within the Framework Specified in the EU White Paper  ‘Strategy for an EU 
Chemicals Policy’ (Web Report W10), Leicester, UK, MRC Institute for Environment and Health (at http://www.le.ac.uk/ieh/ posted December 2001) 
 25 
 Method  
(Annex V and 
OECD) 
Title Min  (Limit2) 
Control/treated 
Max Full Test 
Control/treated 
Normally Comments 
Repeated dose 90 
- day oral toxicity 
study in rodents 
 B.27 Sub-chronic oral 
toxicity test. 
Repeated dose 90 
- day oral toxicity 
study in non-
rodents 
8/8 (limit) 32 8/24 8/243  
 B.28 Sub-chronic 
dermal toxicity 
test: 90-day 
repeated dermal 
dose study using 
rodent species 
20/20 (limit) 120 20(+20)/60  
+ interim (=20) 
-  
 B.29 Sub-chronic 
inhalation toxicity 
test: 90-day 
repeated 
inhalation dose 
study using rodent 
species 
20/20 120 20(+20)/60  
+ interim (=20) 
-  
6.6.3  A long- term repeated toxicity 
study 
B.30 Chronic toxicity 
test 
8/24 160 Rodent 8/24 
Non Rodent 
40/120 
1606  
6.7  Reproductive toxicity 
6.7.1  Screening for  reproductive/-
developmental toxicity 
OECD TG 421 Reproductive/ 
developmental 
toxicity screening 
test 
20/20 80 20/60 803  
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 Method  
(Annex V and 
OECD) 
Title Min  (Limit2) 
Control/treated 
Max Full Test 
Control/treated 
Normally Comments 
6.7.2  Developmental toxicity study B.31 Teratogenicity test 
– rodent and non-
rodent 
never used 144 Non rodent : 24/72 
females + 24/24 
males 
 
Rodent: 16/32 
1003 Pups not counted, 
(females arrive 
pregnant, no 
males) 
6.7.3 and  
6.7.4  Two-generation reproductive 
toxicity study 
B.35 Two generation 
reproduction 
toxicity test 
never used 448 2 x 28 (male  + 
female)/ 2 x 28 x 3 
x 2 generations 
4483 Pups not counted  
6.8  Toxicokinetics 
6.8.1 Assessment of the toxicokinetic 
behaviour of the substance to the extent 
that can be derived from the relevant 
available information 
B.36 Toxicokinetics Depends on study 
design and target, 
but single dose rat 
gives test animal 
use of 22 
1983 22 - 198 603 Min test not 
available. Animal 
use depends on 
test design, 
(single dose/-
repeated 
dose/carcinogenici
ty/reprotoxic). 
6.9    A carcinogenicity study B.32 Carcinogenicity 
test 
300 400 100/300 4006  
7.1 Aquatic toxicity 
7.1.3 Short-term toxicity testing on fish 
 
C.1  Acute Toxicity for 
Fish 
7/7 (limit) 42 7/35 14  
7.1.6  Long-term toxicity testing on fish 
7.1.6.1  Fish early-life stage (FELS) OECD TG 210 Fish early-life 300 4206 60 (+60)/300 4007 Preferred test, 
                                                 
7 estimate after consultation with a Danish test laboratory (DHI) 
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 Method  
(Annex V and 
OECD) 
Title Min  (Limit2) 
Control/treated 
Max Full Test 
Control/treated 
Normally Comments 
toxicity test (OECD  210) stage (FELS) 
toxicity test 
others tests not 
normally 
carried out 
7.3.2 Bioconcentration in (one) aquatic 
species, preferably fish 
C.13 Bioconcentration: 
Flow-through fish 
test 
never  used 108 108 108  
7.6 Reproductive toxicity to birds OECD TG 206 Avian 
reproduction test 
never  used 70 70 70  
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